Search ARM

Q2 2019 Quarterly Report - Europe


This quarterly sector report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.

European Sector Landscape

234+

Regenerative Medicine / Advanced Therapies
Companies based in Europe/Israel

H1 2019 European/Israeli Financings

Total
Global FinancingS

$1.3 Billion
Approximately €1.2 Billion

 17%

YoY increase from H1 2018

Gene & Gene-modified
Cell Therapy

$1.1 Billion
Approximately €1.0 Billion

 9%

YoY increase from H1 2018

Cell
Therapy

$631 Million
Approximately €567 Million

 13%

YoY increase from H1 2018

Tissue
Engineering

$35 Million
Approximately €31 Million

 9%

YoY decrease from H1 2018

266

Clinical Trials
Sponsored by a European or Israeli
developer as of the end of H1 2019

Clinical Trial by Technology Type

Clinical Trials by Phase

Gene Therapy
Cell Therapy
Gene-Modified
Cell Therapy
Tissue Engineering

Clinical Trials by Indication: H1 2019